Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Pharmamar
Thumbnail
June 08, 2022

Aldeyra's tears of joy fail to move investors

Aldeyra gets a win in its second pivotal dry eye trial of reproxalap, but only after some serious tinkering.

Thumbnail
December 21, 2021

Aldeyra needs more Tranquility

A pivotal failure sees the group tinker with a second phase 3 trial, and the delay looks like good news for Bausch.

Article image
Vantage logo
September 09, 2021

World Lung 2021 – Zepzelca salvages pride from the Atlantis wreckage

Full data from the trial position the Pharmamar/Jazz small-cell lung cancer drug to remain safely on the US market.

Article image
Vantage logo
September 03, 2021

World Lung 2021 preview – China challenges and tremelimumab rises

The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.

Article image
Vantage logo
July 05, 2021

Arrowhead pause raises more questions about lung delivery

Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.

Article image
Vantage logo
April 14, 2021

Bausch boosted ahead of eye spin-off

NOV03 posts a pivotal win but the late-stage dry eye pipeline is crowded.

Article image
Vantage logo
February 03, 2021

GW succumbs to a Jazz overture

A focus on rare diseases and regulatory acceptance of cannabis make GW the subject of a $7.2bn buyout.

Article image
Vantage logo
December 03, 2020

Atlantis sinks for Pharmamar and Jazz

Pharmamar’s pivotal small cell lung cancer trial is finally confirmed a dud, but will the FDA pull Zepzelca from the market?

Article image
Vantage logo
September 24, 2020

Esmo 2020 movers – antibody drug conjugates dominate the news flow

Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.

Article image
Vantage logo
July 02, 2020

US FDA approval tracker: June 2020

Article image
Vantage logo
June 24, 2020

Important catalysts approach for smaller biotechs

Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

July 28, 2022

Access Valuable Insights Payer Behaviour Infographic

July 18, 2022

Medtech - Going steady

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.